Cargando…

Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease

Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regul...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuster-Matanzo, Almudena, Jurado-Arjona, Jerónimo, Benvegnù, Stefano, García, Esther, Martín-Maestro, Patricia, Gómez-Sintes, Raquel, Hernández, Félix, Ávila, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309299/
https://www.ncbi.nlm.nih.gov/pubmed/27832289
http://dx.doi.org/10.1007/s00018-016-2408-6
_version_ 1782507686377553920
author Fuster-Matanzo, Almudena
Jurado-Arjona, Jerónimo
Benvegnù, Stefano
García, Esther
Martín-Maestro, Patricia
Gómez-Sintes, Raquel
Hernández, Félix
Ávila, Jesús
author_facet Fuster-Matanzo, Almudena
Jurado-Arjona, Jerónimo
Benvegnù, Stefano
García, Esther
Martín-Maestro, Patricia
Gómez-Sintes, Raquel
Hernández, Félix
Ávila, Jesús
author_sort Fuster-Matanzo, Almudena
collection PubMed
description Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regulate the production and subsequent secretion of fractalkine, a chemokine involved in the immune response that has been linked to AD and to other different neurological disorders. Treatment of primary cultured neurons with GSK-3β inhibitors such as lithium and AR-A014418 decreased full-length fractalkine in total cell extracts. Opposite effects were observed after neuron transduction with a lentiviral vector overexpressing the kinase. Biotinylation assays showed that those changes mainly affect the plasma membrane-associated form of the protein, an observation that positively correlates with changes in the levels of its soluble form. These effects were confirmed in lithium-treated wild type (wt) mice and in GSK-3β transgenic animals, as well as in brain samples from AD patients, evident as age-dependent (animals) or Braak stage dependent changes (humans) in both the membrane-bound and the soluble forms of the protein. Further immunohistochemical analyses demonstrated how GSK-3β exerts these effects by affecting the trafficking of the chemokine from the Golgi to the plasma membrane, in different and opposite ways when the levels/activity of the kinase are increased or decreased. This work provides for the first time a mechanism linking GSK-3β and fractalkine both in vitro and in vivo, with important implications for neurological disorders and especially for AD, in which levels of this chemokine might be useful as a diagnostic tool. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00018-016-2408-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5309299
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-53092992017-02-28 Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease Fuster-Matanzo, Almudena Jurado-Arjona, Jerónimo Benvegnù, Stefano García, Esther Martín-Maestro, Patricia Gómez-Sintes, Raquel Hernández, Félix Ávila, Jesús Cell Mol Life Sci Original Article Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regulate the production and subsequent secretion of fractalkine, a chemokine involved in the immune response that has been linked to AD and to other different neurological disorders. Treatment of primary cultured neurons with GSK-3β inhibitors such as lithium and AR-A014418 decreased full-length fractalkine in total cell extracts. Opposite effects were observed after neuron transduction with a lentiviral vector overexpressing the kinase. Biotinylation assays showed that those changes mainly affect the plasma membrane-associated form of the protein, an observation that positively correlates with changes in the levels of its soluble form. These effects were confirmed in lithium-treated wild type (wt) mice and in GSK-3β transgenic animals, as well as in brain samples from AD patients, evident as age-dependent (animals) or Braak stage dependent changes (humans) in both the membrane-bound and the soluble forms of the protein. Further immunohistochemical analyses demonstrated how GSK-3β exerts these effects by affecting the trafficking of the chemokine from the Golgi to the plasma membrane, in different and opposite ways when the levels/activity of the kinase are increased or decreased. This work provides for the first time a mechanism linking GSK-3β and fractalkine both in vitro and in vivo, with important implications for neurological disorders and especially for AD, in which levels of this chemokine might be useful as a diagnostic tool. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00018-016-2408-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-11-10 2017 /pmc/articles/PMC5309299/ /pubmed/27832289 http://dx.doi.org/10.1007/s00018-016-2408-6 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Fuster-Matanzo, Almudena
Jurado-Arjona, Jerónimo
Benvegnù, Stefano
García, Esther
Martín-Maestro, Patricia
Gómez-Sintes, Raquel
Hernández, Félix
Ávila, Jesús
Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
title Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
title_full Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
title_fullStr Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
title_full_unstemmed Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
title_short Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
title_sort glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from golgi to plasma membrane: implications for alzheimer’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309299/
https://www.ncbi.nlm.nih.gov/pubmed/27832289
http://dx.doi.org/10.1007/s00018-016-2408-6
work_keys_str_mv AT fustermatanzoalmudena glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT juradoarjonajeronimo glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT benvegnustefano glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT garciaesther glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT martinmaestropatricia glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT gomezsintesraquel glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT hernandezfelix glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease
AT avilajesus glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease